Investments
49Portfolio Exits
31Funds
1Partners & Customers
10Service Providers
2Expert Collections containing GlaxoSmithKline
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find GlaxoSmithKline in 3 Expert Collections, including Diabetes.
Diabetes
1,750 items
Medical Devices
412 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Biopharma Tech
260 items
GlaxoSmithKline Web Traffic
GlaxoSmithKline Rank
Research containing GlaxoSmithKline
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned GlaxoSmithKline in 9 CB Insights research briefs, most recently on Feb 16, 2022.

Feb 16, 2022
The 130+ AI startups reinventing healthcare

Dec 17, 2020
5 Ways Digital Twins Could Improve Healthcare
Nov 11, 2020
Genomics Business Model Spotlight: HelixLatest GlaxoSmithKline News
May 15, 2022
Source: Papi A, et al. The New England Journal of Medicine and JAMA Discussion on the Edge: Reports of Recently Published Pulmonary Research. Disclosures: Chipps reports consulting for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron and Sanofi. Papi reports receiving grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini and Sanofi/Regeneron; personal fees from Edmond Pharma, Mundipharma, Novartis, Roche and Zambon; grants from Fondazione Maugeri and Fondazione Chiesi; and advising for Bond Avillion 2 Development LP. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio SAN FRANCISCO — In patients with uncontrolled moderate to severe asthma, a fixed-dose combination of albuterol and budesonide used as an as-needed rescue medication lowered risk for severe asthma exacerbations compared with albuterol alone. “MANDALA met its primary endpoint: Albuterol-budesonide significantly reduced exacerbation risk vs. albuterol,” Alberto Papi, MD, professor of respiratory medicine at University of Ferrara Medical School in Italy, said during a presentation of the findings at the American Thoracic Society International Conference. Results were simultaneously published in The New England Journal of Medicine. Source: Adobe Stock. In a preplanned efficacy analysis, the primary endpoint of time to first severe asthma exacerbation was 27% lower among patients assigned a fixed-dose combination of albuterol 180 µg and budesonide 160 µg compared with albuterol 180 µg alone (HR = 0.73; 95% CI, 0.61-0.88; P < .001) and 17% lower with a lower-dose combination of albuterol 180 µg and budesonide 80 µg (HR = 0.83; 95% CI, 0.7-0.99; P = .041). In an intention-to-treat analysis, risk was reduced by 26% with the higher-dose combination (HR = 0.74; 95% CI, 0.62-0.89; P = .001) and 16% with the lower-dose combination (HR = 0.84; 95% CI, 0.71-1; P = .052), Papi said during the presentation. The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication containing the short-acting beta 2 agonist albuterol and the inhaled corticosteroid budesonide in the U.S. It is being developed by AstraZeneca and Avillion, according to a company press release. Bradley Chipps The fixed-dose combination rescue inhaler was developed to provide rapid relief of asthma symptoms and simultaneously treat the variability of underlying inflammation when needed most, according to Papi. “Albuterol by itself, although it works initially with good bronchodilatation, does not affect the inflammatory component of asthma and as a result does not prevent exacerbations. We know one-third to 45% of patients with mild asthma exacerbate every year. We need to intervene in the ‘window of opportunity,’ which is when asthma control lessens when people become more symptomatic to prevent their progression to an exacerbation,” Bradley E. Chipps, MD, past president of the American College of Allergy, Asthma and Immunology and medical director of the Capital Allergy & Respiratory Disease Center in Sacramento, California, told Healio. The take-home message of this trial is: “You can keep your patients from having to take oral corticosteroids. No matter what you think your patients do, many don’t take their medications; they view asthma as an episodic disease. This [fixed-dose combination rescue inhaler] helps to stop episodic increases in symptoms prior to progressing to an exacerbation,” Chipps said. The phase 3, double-blind, randomized, event-driven trial enrolled symptomatic patients aged 4 years and older with moderate to severe asthma and at least one severe exacerbation in the prior year. The mean age was about 49 years, two-thirds were female and 81% were white. A total of 3,132 patients were randomly assigned to the higher-dose group, lower-dose group or albuterol only; of those, only 183 were aged 4 years to younger than 18 years. The study medication was administered via pressurized metered-dose inhaler in two actuations. All patients were receiving maintenance inhaled corticosteroids alone or combined with other controller medications. The fixed-dose combination also reduced mean annualized total systemic corticosteroid exposure and the annualized severe exacerbation rate, according to the NEJM publication. Researchers reported numerically higher odds of improvement in symptom control and quality of life with the fixed-dose combination. The incidence of any adverse event was similar across the three groups, at 46.2% in the higher-dose combination group, 47.1% in the lower-dose combination group and 46.4% in the albuterol-only group. Serious adverse events occurred in 5.2%, 3.8% and 4.5%, respectively. Adverse events were consistent with the known safety profiles of the individual components; the most common adverse events were nasopharyngitis, headache and upper respiratory tract infection. “Given the efficacy of adding budesonide to albuterol as a rescue medication and the duration of the treatment, we believe that this is going to be potentially a change in the paradigm of the use of rescue medication,” Papi said. Three phase 3 studies evaluating albuterol-budesonide fixed-dose combination as pressurized meter-dose inhaler in patients with asthma are now completed: TYREE , MANDALA and DENALI. DENALI will be presented at a later date during the ATS International Conference; this article will be updated. References:
GlaxoSmithKline Investments
49 Investments
GlaxoSmithKline has made 49 investments. Their latest investment was in LifeMine Therapeutics as part of their Series C on March 3, 2022.
GlaxoSmithKline Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/23/2022 | Series C | LifeMine Therapeutics | $175M | Yes | 12 | |
1/18/2022 | Corporate Minority - P2P | 23andMe | $51M | No | 1 | |
7/20/2020 | Series G - II | CureVac | $297M | Yes | 8 | |
4/6/2020 | Corporate Minority - P2P | |||||
4/1/2019 | Series B |
Date | 3/23/2022 | 1/18/2022 | 7/20/2020 | 4/6/2020 | 4/1/2019 |
---|---|---|---|---|---|
Round | Series C | Corporate Minority - P2P | Series G - II | Corporate Minority - P2P | Series B |
Company | LifeMine Therapeutics | 23andMe | CureVac | ||
Amount | $175M | $51M | $297M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 12 | 1 | 8 |
GlaxoSmithKline Portfolio Exits
31 Portfolio Exits
GlaxoSmithKline has 31 portfolio exits. Their latest portfolio exit was 23andMe on June 17, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/17/2021 | Reverse Merger | 13 | |||
6/15/2021 | Divestiture | GlaxoSmithKline - Baldriparan, Formigran, Spalt, and Kamol Brands | 2 | ||
2/11/2021 | Divestiture | 6 | |||
Date | 6/17/2021 | 6/15/2021 | 2/11/2021 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | Divestiture | Divestiture | ||
Companies | GlaxoSmithKline - Baldriparan, Formigran, Spalt, and Kamol Brands | ||||
Valuation | |||||
Acquirer | |||||
Sources | 13 | 2 | 6 |
GlaxoSmithKline Acquisitions
20 Acquisitions
GlaxoSmithKline acquired 20 companies. Their latest acquisition was Sierra Oncology on April 13, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
4/13/2022 | Series D | $79.83M | Acq - Pending | 6 | ||
9/11/2019 | Series A | $10M | Acquired | 6 | ||
12/19/2018 | Other | Corporate Majority | 2 | |||
12/3/2018 | Series B | |||||
3/27/2018 | Other |
Date | 4/13/2022 | 9/11/2019 | 12/19/2018 | 12/3/2018 | 3/27/2018 |
---|---|---|---|---|---|
Investment Stage | Series D | Series A | Other | Series B | Other |
Companies | |||||
Valuation | |||||
Total Funding | $79.83M | $10M | |||
Note | Acq - Pending | Acquired | Corporate Majority | ||
Sources | 6 | 6 | 2 |
GlaxoSmithKline Fund History
1 Fund History
GlaxoSmithKline has 1 fund, including Action Potential Venture Capital Ltd..
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
8/8/2013 | Action Potential Venture Capital Ltd. | Multi-Stage Venture Capital | Closed | $50M | 1 |
Closing Date | 8/8/2013 |
---|---|
Fund | Action Potential Venture Capital Ltd. |
Fund Type | Multi-Stage Venture Capital |
Status | Closed |
Amount | $50M |
Sources | 1 |
GlaxoSmithKline Partners & Customers
10 Partners and customers
GlaxoSmithKline has 10 strategic partners and customers. GlaxoSmithKline recently partnered with Vir Biotechnology on April 4, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/6/2022 | Partner | United States | GSK and Vir Biotechnology both maintain that the treatment is effective against BA .2 despite disagreement from the scientific community . | 1 | |
4/5/2022 | Partner | United States | PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development `` Our partnership will combine GlaxoSmithKline and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' said Andrew Beck , CEO and Co-founder of PathAI . | 2 | |
4/5/2022 | Vendor | United States | AI-powered pathology startup PathAI teams up with GSK for drug discovery `` Our partnership will combine GSK and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' PathAI CEO and cofounder Andrew Beck said in a statement . | 2 | |
3/25/2022 | Partner | ||||
3/23/2022 | Licensor |
Date | 4/6/2022 | 4/5/2022 | 4/5/2022 | 3/25/2022 | 3/23/2022 |
---|---|---|---|---|---|
Type | Partner | Partner | Vendor | Partner | Licensor |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | GSK and Vir Biotechnology both maintain that the treatment is effective against BA .2 despite disagreement from the scientific community . | PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development `` Our partnership will combine GlaxoSmithKline and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' said Andrew Beck , CEO and Co-founder of PathAI . | AI-powered pathology startup PathAI teams up with GSK for drug discovery `` Our partnership will combine GSK and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' PathAI CEO and cofounder Andrew Beck said in a statement . | ||
Sources | 1 | 2 | 2 |
GlaxoSmithKline Service Providers
2 Service Providers
GlaxoSmithKline has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor | |
Service Provider | ||
---|---|---|
Associated Rounds | Acq - P2P | |
Provider Type | Investment Bank | |
Service Type | Financial Advisor |
Partnership data by VentureSource
GlaxoSmithKline Team
91 Team Members
GlaxoSmithKline has 91 team members, including current President, Hal V Barron.
Name | Work History | Title | Status |
---|---|---|---|
Hal V Barron | President | Current | |
Simon Dingemans | Chief Financial Officer | Current | |
Manjeet Aujla | Chief Information Officer, Senior Vice President | Current | |
Vincent Brichard | Senior Vice President | Current | |
Robin Carr, | Senior Vice President | Current |
Name | Hal V Barron | Simon Dingemans | Manjeet Aujla | Vincent Brichard | Robin Carr, |
---|---|---|---|---|---|
Work History | |||||
Title | President | Chief Financial Officer | Chief Information Officer, Senior Vice President | Senior Vice President | Senior Vice President |
Status | Current | Current | Current | Current | Current |
You May Also Like
Janssen Pharmaceuticals is a pharmaceutical company that provides medicines for an array of health concerns in several therapeutic areas. These include: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer's disease, epilepsy, migraine prevention and treatment), pain management, and women's health.
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and inflammatory conditions. They are also committed to independent thinking and ground breaking solutions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting‐edge treatments to meet the most pressing needs of healthcare professionals and patients.
The Grunenthal Group is a science-based pharmaceutical company that seeks to bring treatments and technologies to patients worldwide. The company focuses on pain management and related diseases.
Eli Lilly and Company (NYSE: LLY) is a global healthcare company that unites caring with discovery to make life better for people around the world. Lilly works to discover and bring medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Roche Holding is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.